LBA20 Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 31; p. S1151
Main Authors Jones, R., Casbard, A., Carucci, M., Smith, J., Ingarfield, K., Gee, J.M.W., Hudson, Z., Alchami, F., Hayward, L., Hickish, T., Hwang, D., McAdam, K., Spensley, S., Waters, S., Wheatley, D., Beresford, M.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2020
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2020.08.2248